Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 By: BiomX Inc. via Business Wire August 07, 2022 at 03:17 AM EDT BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com. About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Additional information is available at www.biomx.com, the content of which does not form a part of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20220807005015/en/Contacts BiomX, Inc. Anat Primovich Corporate Project Manager +97250-6977228 anatp@biomx.com Investor Relations: LifeSci Advisors, LLC John Mullaly jmullaly@lifesciadvisors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 By: BiomX Inc. via Business Wire August 07, 2022 at 03:17 AM EDT BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com. About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Additional information is available at www.biomx.com, the content of which does not form a part of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20220807005015/en/Contacts BiomX, Inc. Anat Primovich Corporate Project Manager +97250-6977228 anatp@biomx.com Investor Relations: LifeSci Advisors, LLC John Mullaly jmullaly@lifesciadvisors.com
BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com. About BiomX BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Additional information is available at www.biomx.com, the content of which does not form a part of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20220807005015/en/
BiomX, Inc. Anat Primovich Corporate Project Manager +97250-6977228 anatp@biomx.com Investor Relations: LifeSci Advisors, LLC John Mullaly jmullaly@lifesciadvisors.com